J&J submits sNDA for Invokana after premature end to clinical trial

29th March 2019 Uncategorised 0

If approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease.

More: J&J submits sNDA for Invokana after premature end to clinical trial
Source: News